Wiki source
Senolytics and Senomorphics
A read-only view of this entry as wiki markup. This atlas is curated, so editing is disabled — but the source shows exactly how the page is structured.
# Senolytics and Senomorphics Portal: Longevity Science Stage: Early human studies Evidence: Early human Template: Drug platform Risk: Moderate Reversibility: Context dependent Last reviewed: May 2026 == Summary == Drugs that remove or quiet senescent cells could reduce inflammatory aging signals, but benefits depend heavily on context. == Key takeaways == * Senescent cells can be harmful, protective, or useful depending on timing and tissue. * Intermittent dosing is attractive because the target accumulates over time. * Frailty, fibrosis, metabolic disease, and immune aging remain major areas to watch. == Mechanism == Senolytics try to selectively kill senescent cells. Senomorphics try to reduce the inflammatory secretions those cells produce without necessarily removing them. The central design problem is selectivity. A therapy that broadly damages stressed but useful cells can undermine repair, wound healing, or immune function. == Practical interpretation == Aging biology rarely maps to a single villain. Senescence is part of cancer suppression and tissue repair, so timing matters as much as the molecular target. The best evidence will come from endpoints tied to function: mobility, organ performance, fibrosis, immune response, and recovery after stress. == Open questions == * In which contexts does clearing senescent cells help versus harm? * What are the right dosing schedules? == Watchlist == * Intermittent protocols * Combination therapies * Frailty endpoints * Inflammatory biomarkers == References == * Human senolytic pilot — Hickson et al., EBioMedicine, 2019. https://pubmed.ncbi.nlm.nih.gov/31542391/. Preliminary human dasatinib plus quercetin study in diabetic kidney disease. * Senolytic clinical follow-up — Senolytic combination clinical literature, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC10852012/. Use for inflammation, tissue specificity, and clinical endpoint caution. == Categories == [[Category:Longevity Science]] [[Category:senescence]] [[Category:inflammation]] [[Category:geroscience]]